Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint

Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint

(MedPage Today) -- Survodutide, an investigational glucagon receptor and GLP-1 receptor dual agonist, was safe for patients with obesity and either established cardiovascular disease (CVD), chronic kidney disease (CKD), or increased risk of CVD...

Boehringer's experimental obesity injection passed a heart-safety test—but researchers have not shown it protects the heart

A large trial found that experimental obesity drug survodutide did not increase major cardiovascular risks, but it has not been shown to protect the heart and caused frequent digestive side effects.

Boehringer Ingelheim Reports Cardiovascular Safety and Metabolic Findings for Survodutide in Phase III Trial

SYNCHRONIZE-CVOT met its non-inferiority endpoint for major cardiovascular events and showed changes in blood pressure, waist circumference and weight at Week 72. IN BRIEFKEY TAKEAWAYSFAQs Boehringer Ingelheim announced that the Phase III SYNCHRONIZE-CVOT study of investigational survodutide met its cardiovascular … Read the full press release →

Boehringer Ingelheim's survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase III SYNCHRONIZE-CVOT trial alongside significant cardiometabolic benefits

SYNCHRONIZE-CVOT met its primary endpoint demonstrating the safety of survodutide in terms of major adverse cardiovascular events compared with placebo in people with obesity and established cardiovascular disease (CVD), chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD.1 Survodutide also demonstrated meaningful improvements across multiple cardiometabolic measures, including significant reductions …